These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 29080899

  • 1. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
    Ma Y, Liu W, Zhang L, Jia G.
    Med Sci Monit; 2017 Oct 29; 23():5150-5157. PubMed ID: 29080899
    [Abstract] [Full Text] [Related]

  • 2. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L, Ma YP, Jia G.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov 29; 33(11):926-31. PubMed ID: 23363750
    [Abstract] [Full Text] [Related]

  • 3. [Inhibitory effect of histone deacetylase inhibitor LBH589 on multiple myeloma MM1R cells in vitro].
    Zhang L, Ma YP, Jia G, Lu YJ, Zhang L, Lu H, Chang MX.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct 29; 20(5):1122-6. PubMed ID: 23114131
    [Abstract] [Full Text] [Related]

  • 4. Multiple mechanisms contribute to the synergistic anti-myeloma activity of the pan-histone deacetylase inhibitor LBH589 and the rapalog RAD001.
    Ramakrishnan V, Kimlinger T, Timm M, Haug J, Rajkumar SV, Kumar S.
    Leuk Res; 2014 Nov 29; 38(11):1358-66. PubMed ID: 25282334
    [Abstract] [Full Text] [Related]

  • 5. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
    Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, Gutiérrez N, Atadja P, Pandiella A, San Miguel JF.
    Cancer Res; 2006 Jun 01; 66(11):5781-9. PubMed ID: 16740717
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [MS-275, a histone deacetylase inhibitor, induces apoptosis and alters survivin gene expression in human myeloma cell line U266].
    Ma J, Zhao M, Yu XD, Wang ZH.
    Ai Zheng; 2009 May 01; 28(5):466-71. PubMed ID: 19624872
    [Abstract] [Full Text] [Related]

  • 10. [Reversal effect of LBH589 alone or in combination with bortezomib on drug-resistance in myeloid leukemia and its mechanism].
    Jiang XJ, Meng FY, Zhou HS, Wang Q, Wu FQ, Huang KK, Huang M, Wang ZX, Chen WW.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Aug 01; 32(8):537-42. PubMed ID: 22338177
    [Abstract] [Full Text] [Related]

  • 11. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
    Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC.
    Blood; 2006 Nov 15; 108(10):3441-9. PubMed ID: 16728695
    [Abstract] [Full Text] [Related]

  • 12. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
    Yan-Fang T, Zhi-Heng L, Li-Xiao X, Fang F, Jun L, Gang L, Lan C, Na-Na W, Xiao-Juan D, Li-Chao S, Wen-Li Z, Pei-Fang X, He Z, Guang-Hao S, Yan-Hong L, Yi-Ping L, Yun-Yun X, Hui-Ting Z, Yi W, Mei-Fang J, Lin L, Jian N, Shao-Yan H, Xue-Ming Z, Xing F, Jian W, Jian P.
    PLoS One; 2015 Nov 15; 10(7):e0126566. PubMed ID: 26176219
    [Abstract] [Full Text] [Related]

  • 13. The histone deacetylase inhibitor LBH589 enhances the anti-myeloma effects of chemotherapy in vitro and in vivo.
    Sanchez E, Shen J, Steinberg J, Li M, Wang C, Bonavida B, Chen H, Li ZW, Berenson JR.
    Leuk Res; 2011 Mar 15; 35(3):373-9. PubMed ID: 20650529
    [Abstract] [Full Text] [Related]

  • 14. Crucial role of HO-1/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma.
    Tang S, Ma D, Cheng B, Fang Q, Kuang X, Yu K, Wang W, Hu B, Wang J.
    Exp Cell Res; 2018 Feb 15; 363(2):196-207. PubMed ID: 29317217
    [Abstract] [Full Text] [Related]

  • 15. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY, Dai Y, Grant S.
    Clin Cancer Res; 2004 Jun 01; 10(11):3839-52. PubMed ID: 15173093
    [Abstract] [Full Text] [Related]

  • 16. DAPK plays an important role in panobinostat-induced autophagy and commits cells to apoptosis under autophagy deficient conditions.
    Gandesiri M, Chakilam S, Ivanovska J, Benderska N, Ocker M, Di Fazio P, Feoktistova M, Gali-Muhtasib H, Rave-Fränk M, Prante O, Christiansen H, Leverkus M, Hartmann A, Schneider-Stock R.
    Apoptosis; 2012 Dec 01; 17(12):1300-15. PubMed ID: 23011180
    [Abstract] [Full Text] [Related]

  • 17. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
    Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, Boise LH, Lee KP, Nikiforov MA.
    Blood; 2012 Feb 09; 119(6):1450-8. PubMed ID: 22144178
    [Abstract] [Full Text] [Related]

  • 18. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
    Lin L, Chen D, Xiang ZF, Pei RZ, Zhang PS, Liu XH, Du XH, Lu Y.
    Cancer Biomark; 2017 Aug 23; 20(2):217-224. PubMed ID: 28869453
    [Abstract] [Full Text] [Related]

  • 19. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.
    Maschauer S, Gahr S, Gandesiri M, Tripal P, Schneider-Stock R, Kuwert T, Ocker M, Prante O.
    Nucl Med Biol; 2016 Jan 23; 43(1):27-34. PubMed ID: 26702784
    [Abstract] [Full Text] [Related]

  • 20. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD.
    BMC Med Genomics; 2009 Nov 30; 2():67. PubMed ID: 19948057
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.